Abeona Therapeutics Inc.
ABEO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -100% | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $1 |
| Gross Profit | -$0 | $0 | $0 | -$1 |
| % Margin | – | 75% | – | – |
| R&D Expenses | $4 | $6 | $10 | $9 |
| G&A Expenses | $0 | $17 | $10 | $0 |
| SG&A Expenses | $19 | $17 | $10 | $7 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $24 | $23 | $20 | $16 |
| Operating Income | -$24 | -$23 | -$20 | -$17 |
| % Margin | – | -5,698% | – | – |
| Other Income/Exp. Net | $4 | $147 | $8 | $7 |
| Pre-Tax Income | -$20 | $124 | -$12 | -$9 |
| Tax Expense | -$15 | $16 | $0 | $0 |
| Net Income | -$5 | $109 | -$12 | -$9 |
| % Margin | – | 27,208.3% | – | – |
| EPS | -0.1 | 2.07 | -0.24 | -0.23 |
| % Growth | -104.8% | 962.5% | -4.3% | – |
| EPS Diluted | -0.1 | 1.71 | -0.24 | -0.23 |
| Weighted Avg Shares Out | 54 | 53 | 50 | 41 |
| Weighted Avg Shares Out Dil | 54 | 67 | 50 | 41 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $1 | $1 | $1 |
| Interest Expense | $1 | $1 | $1 | $1 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | -$19 | $126 | -$10 | -$7 |
| % Margin | – | 31,517.5% | – | – |